Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2020; 11:1006-1006.

Enhanced tumorigenicity by mitochondrial DNA mild mutations

Alberto Cruz-Bermúdez _, Carmen G. Vallejo, Ramiro J. Vicente-Blanco, María Esther Gallardo, Miguel Ángel Fernández-Moreno, Miguel Quintanilla and Rafael Garesse

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:13628-13643. https://doi.org/10.18632/oncotarget.3698

Metrics: PDF 1233 views  |   HTML 1985 views  |   ?  


Abstract

Alberto Cruz-Bermúdez1,2,3, Carmen G. Vallejo1, Ramiro J. Vicente-Blanco1,2, María Esther Gallardo1,2,3, Miguel Ángel Fernández-Moreno1,2,3, Miguel Quintanilla1,4 and Rafael Garesse1,2,3

1 Instituto de Investigaciones Biomédicas “Alberto Sols”, Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Madrid, Spain

2 Departamento de Bioquímica and Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Facultad de Medicina, UAM, Madrid, Spain

3 Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, Spain

4 Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Madrid, Spain

Correspondence to:

Miguel Quintanilla, email:

Rafael Garesse, email:

Keywords: cancer, mitochondria, mtDNA mutations, LHON, retrograde signaling

Received: January 14, 2015 Accepted: March 02, 2015 Published: March 30, 2015

Abstract

To understand how mitochondria are involved in malignant transformation we have generated a collection of transmitochondrial cybrid cell lines on the same nuclear background (143B) but with mutant mitochondrial DNA (mtDNA) variants with different degrees of pathogenicity. These include the severe mutation in the tRNALys gene, m.8363G>A, and the three milder yet prevalent Leber’s hereditary optic neuropathy (LHON) mutations in the MT-ND1 (m.3460G>A), MT-ND4 (m.11778G>A) and MT-ND6 (m.14484T>C) mitochondrial genes. We found that 143B ρ0 cells devoid of mtDNA and cybrids harboring wild type mtDNA or that causing severe mitochondrial dysfunction do not produce tumors when injected in nude mice. By contrast cybrids containing mild mutant mtDNAs exhibit different tumorigenic capacities, depending on OXPHOS dysfunction.

The differences in tumorigenicity correlate with an enhanced resistance to apoptosis and high levels of NOX expression. However, the final capacity of the different cybrid cell lines to generate tumors is most likely a consequence of a complex array of pro-oncogenic and anti-oncogenic factors associated with mitochondrial dysfunction.

Our results demonstrate the essential role of mtDNA in tumorigenesis and explain the numerous and varied mtDNA mutations found in human tumors, most of which give rise to mild mitochondrial dysfunction.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3698